摘要
本文对近20年来单药或联合化疗方案治疗恶性间皮瘤疗效的临床试验进行综述,但结果令人失望。罕有报告有效率>20%者,且均不能使中数生存期>10个月,新药培美曲赛类药物的出现使恶性间皮瘤治疗出现明显进展,与顺铂合用有效率可达45%,中数生存期超过12个月,以这2个药为基础的方案现已成为治疗恶性胸膜间皮瘤的标准一线方案。
It is reviewed that clinical trials of single agent or combined chemotherapy regiments treated malignant mesothelioma have been done in these 20 years. But their results were poor. The response rate of few agents was greater than 20%. None of drugs could improve median survival beyond 10 months. New drug-pemetrexed produced by recent year obtained encouraging result to treat malignant mesothelioma in phase I1 and phase 11 clinical trials. Specially, pemethrexed combined with cisplatin could obtain response rates of up to 45%, and improve median survival to over 12 months. The doublet - based chemotherapy regiment has become the first - line standard regiment of malignant pleural mesothelioma （MPM）.
出处
《癌症进展》
2006年第6期534-539,共6页
Oncology Progress
关键词
恶性间皮瘤
化疗
malignant mesothelioma chemotherapy
